<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03689595</url>
  </required_header>
  <id_info>
    <org_study_id>18-370</org_study_id>
    <nct_id>NCT03689595</nct_id>
  </id_info>
  <brief_title>Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)</brief_title>
  <official_title>Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stand Up To Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PROMISE Study aims to establish a prospective cohort of individuals with precursor
      conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance
      (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to
      identify risk factors for progression to symptomatic multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of the PROMISE research study is to determine clinical/genomic alterations present
      in individuals with MGUS and SMM, who are diagnosed though screening of a high-risk
      population. We also seek to determine clinical/genomic/epigenetic and immune environmental
      predictors of progression to multiple myeloma in patients with MGUS and SMM.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2033</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2033</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression (TTP) from MGUS/SMM to overt multiple myeloma.</measure>
    <time_frame>15 years</time_frame>
    <description>Progression to symptomatic multiple myeloma</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50000</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Specimen Collection</arm_group_label>
    <description>Samples of blood (2-4 tablespoons) from 3 tubes will be collected
Analysis will be performed on the blood to test for multiple myeloma precursor conditions once sent to outside labs at Mayo Clinic and the Broad Institute</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sample of Blood</intervention_name>
    <description>Collection of blood sample from participants</description>
    <arm_group_label>Specimen Collection</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All special populations who fall within the eligible high-risk age range, ≥ 45 and ≤75
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 45 and ≤75

          -  AA race (self-identified) and/or first-degree relative of a patient with plasma cell
             dyscrasia such as MGUS, SMM, multiple myeloma, and Waldenström Macroglobulinemia

        Exclusion Criteria:

        * Persons diagnosed with cancer at any site (including hematologic cancers) with
        symptomatic disease requiring active therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Ghobrial, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irene Ghobrial, MD</last_name>
    <phone>617-632-4198</phone>
    <email>Irene_Ghobrial@dfci.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Ghobrial, MD</last_name>
      <phone>617-632-4198</phone>
      <email>Irene_Ghobrial@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Irene Ghobrial, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Irene Ghobrial, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

